Industry Research Reports

Home > Reports > Service & Software > AI Clinical Trial Design Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

AI Clinical Trial Design Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Industry: Service & Software

Published Date: 2026-07-16

Pages: 146 Pages

Report ld: 6976657

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

AI Clinical Trial Design Software Market Size(US$)

CAGR 2026-2032

18.8%

Market Size,2032

USD 1,628

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 579 million

Market Forecast in 2032(Value)

US$ 1,628 million

CAGR

18.8%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for AI Clinical Trial Design Software was estimated to be worth US$ 486 million in 2025 and is projected to reach US$ 1628 million, growing at a CAGR of 18.8% from 2026 to 2032.

AI clinical trial design software embeds machine learning, generative AI, statistical modeling, real-world data, and trial simulation into study design workflows. It is used to generate or optimize protocols, eligibility criteria, endpoints, sample sizes, dosing, study arms, site and enrollment assumptions, and to assess probability of success, patient burden, and amendment risk. Products are typically delivered as SaaS platforms, enterprise software, or software bundled with expert services for pharmaceutical companies, biotechnology firms, contract research organizations, medical device companies, and research institutions; the blended gross margin is approximately 78%.

Rising protocol complexity, enrollment delays, amendments, and the high cost of failed studies are pushing sponsors to adopt data-driven design tools before study launch. AI software is expanding beyond sample-size calculation and point feasibility checks into protocol generation, eligibility optimization, endpoint selection, virtual population simulation, probability-of-success forecasting, and patient-burden assessment, making it an increasingly important foundation for clinical development decisions and portfolio prioritization.

Competition includes traditional statistical software vendors, clinical data platform providers, and AI-native companies. Procurement is shifting toward validated models, traceable outputs, broad real-world data coverage, regulatory-standard compatibility, enterprise integration, and human-in-the-loop review. Product development is moving toward structured digital protocols, generative authoring, Bayesian and adaptive simulation, digital twins, and continuous forecasting from design through execution, while high-risk decisions still require review by biostatistics, medical, and regulatory experts.

Large pharmaceutical companies in North America and Europe remain the core customer base, while innovative biotechnology firms, contract research organizations, and clinical development teams in Asia-Pacific are adopting more rapidly. On-premises and private-cloud demand is driven by data security and intellectual-property constraints, whereas SaaS supports faster adoption by smaller customers. The strongest opportunities are in software that reduces rework, improves operational feasibility, and produces regulator-ready, explainable evidence; key risks include biased training data, weak cross-indication generalization, unclear accountability, and substitution by internally developed models.

This report provides a comprehensive view of the global market for AI Clinical Trial Design Software, covering total sales revenue, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.

The AI Clinical Trial Design Software market size, estimations, and forecasts are presented in terms of sales revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding AI Clinical Trial Design Software.

MARKET SEGMENTATION

By Company

Medidata
IQVIA
Certara
Cytel
TriNetX
Saama
Simulations Plus
Statsols
ConcertAI
Phesi
Faro Health
QuantHealth
Unlearn
MMS
Berry Consultants
ZS
Clinion
Nurocor
Lindus Health
TrialKey
Protocol Builder

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

End-to-End Trial Design Platforms
Protocol Authoring and Optimization Software
Trial Simulation and Outcome Prediction Software
Adaptive and Bayesian Design Software
Feasibility and Enrollment Design Software
Synthetic Control and Digital Twin Software

Segment by Application

Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Medical Device and Diagnostics Companies
Academic and Medical Research Institutions
Government and Nonprofit Research Organizations
Other Clinical Research Organizations

Segment by Category

Cloud-Based Software
On-Premises Software
Hybrid Deployment Software

Segment by Division

Standalone Software
Enterprise Platform Suite
Software with Expert Services

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the scope of the report and the global market size (value). It also summarizes market dynamics and recent developments; identifies key drivers and restraints; outlines challenges and risks for players; reviews relevant industry policies.

Chapter 2: Provides a detailed analysis of the AI Clinical Trial Design Software companies' competitive landscape—including revenue shares, recent development plans, and mergers and acquisitions (M&A).

Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 5: Presents AI Clinical Trial Design Software revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.

Chapter 6: Presents AI Clinical Trial Design Software revenue at the country level. It provides segmented data by Type and by Application for each country/region.

Chapter 7: Profiles key players, detailing the main companies' product revenue, gross margin, product portfolios, recent developments, etc.

Chapter 8: Analysis of Value Chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 AI Clinical Trial Design Software Product Introduction

1.2 Global AI Clinical Trial Design Software Market Size Forecast (2021–2032)

1.3 AI Clinical Trial Design Software Market Trends & Drivers

1.3.1 AI Clinical Trial Design Software Industry Trends

1.3.2 AI Clinical Trial Design Software Market Drivers & Opportunities

1.3.3 AI Clinical Trial Design Software Market Challenges

1.3.4 AI Clinical Trial Design Software Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global AI Clinical Trial Design Software Players Revenue Ranking (2025)

2.2 Global AI Clinical Trial Design Software Revenue by Company (2021–2026)

2.3 Key Companies’ R&D and Operations Footprint and Headquarters

2.4 Key Companies AI Clinical Trial Design Software Product Offerings

2.5 Key Companies General Availability (GA) Timeline for AI Clinical Trial Design Software

2.6 AI Clinical Trial Design Software Market Competitive Analysis

2.6.1 AI Clinical Trial Design Software Market Concentration Rate (2021–2026)

2.6.2 Top 5 and Top 10 Global Companies by AI Clinical Trial Design Software Revenue in 2025

2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on AI Clinical Trial Design Software revenue, 2025

2.7 Mergers & Acquisitions and Expansion

3 Segmentation AI Clinical Trial Design Software Market Classification

3.1 Introduction by Type

3.1.1 End-to-End Trial Design Platforms

3.1.2 Protocol Authoring and Optimization Software

3.1.3 Trial Simulation and Outcome Prediction Software

3.1.4 Adaptive and Bayesian Design Software

3.1.5 Feasibility and Enrollment Design Software

3.1.6 Synthetic Control and Digital Twin Software

3.1.7 Global AI Clinical Trial Design Software Sales Value by Type

3.1.7.1 Global AI Clinical Trial Design Software Sales Value by Type (2021 vs 2025 vs 2032)

3.1.7.2 Global AI Clinical Trial Design Software Sales Value, by Type (2021–2032)

3.1.7.3 Global AI Clinical Trial Design Software Sales Value, by Type (%), 2021–2032

3.2 Introduction by Deployment Model

3.2.1 Cloud-Based Software

3.2.2 On-Premises Software

3.2.3 Hybrid Deployment Software

3.2.4 Global AI Clinical Trial Design Software Sales Value by Deployment Model

3.2.4.1 Global AI Clinical Trial Design Software Sales Value by Deployment Model (2021 vs 2025 vs 2032)

3.2.4.2 Global AI Clinical Trial Design Software Sales Value, by Deployment Model (2021–2032)

3.2.4.3 Global AI Clinical Trial Design Software Sales Value, by Deployment Model (%), 2021–2032

3.3 Introduction by Delivery Model

3.3.1 Standalone Software

3.3.2 Enterprise Platform Suite

3.3.3 Software with Expert Services

3.3.4 Global AI Clinical Trial Design Software Sales Value by Delivery Model

3.3.4.1 Global AI Clinical Trial Design Software Sales Value by Delivery Model (2021 vs 2025 vs 2032)

3.3.4.2 Global AI Clinical Trial Design Software Sales Value, by Delivery Model (2021–2032)

3.3.4.3 Global AI Clinical Trial Design Software Sales Value, by Delivery Model (%), 2021–2032

3.4 Introduction by Trial Stage Coverage

3.4.1 Early-Phase Trial Software

3.4.2 Late-Phase Trial Software

3.4.3 Post-Market Study Software

3.4.4 Multi-Phase Trial Software

3.4.5 Global AI Clinical Trial Design Software Sales Value by Trial Stage Coverage

3.4.5.1 Global AI Clinical Trial Design Software Sales Value by Trial Stage Coverage (2021 vs 2025 vs 2032)

3.4.5.2 Global AI Clinical Trial Design Software Sales Value, by Trial Stage Coverage (2021–2032)

3.4.5.3 Global AI Clinical Trial Design Software Sales Value, by Trial Stage Coverage (%), 2021–2032

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Pharmaceutical and Biotechnology Companies

4.1.2 Contract Research Organizations

4.1.3 Medical Device and Diagnostics Companies

4.1.4 Academic and Medical Research Institutions

4.1.5 Government and Nonprofit Research Organizations

4.1.6 Other Clinical Research Organizations

4.2 Global AI Clinical Trial Design Software Sales Value by Application

4.2.1 Global AI Clinical Trial Design Software Sales Value by Application (2021 vs 2025 vs 2032)

4.2.2 Global AI Clinical Trial Design Software Sales Value by Application (2021–2032)

4.2.3 Global AI Clinical Trial Design Software Sales Value by Application (%), 2021–2032

5 Segmentation by Region

5.1 Global AI Clinical Trial Design Software Sales Value by Region

5.1.1 Global AI Clinical Trial Design Software Sales Value by Region: 2021 vs 2025 vs 2032

5.1.2 Global AI Clinical Trial Design Software Sales Value by Region (2021–2026)

5.1.3 Global AI Clinical Trial Design Software Sales Value by Region (2027–2032)

5.1.4 Global AI Clinical Trial Design Software Sales Value by Region (%), 2021–2032

5.2 North America

5.2.1 North America AI Clinical Trial Design Software Sales Value, 2021–2032

5.2.2 North America AI Clinical Trial Design Software Sales Value by Country (%), 2025 vs 2032

5.3 Europe

5.3.1 Europe AI Clinical Trial Design Software Sales Value, 2021–2032

5.3.2 Europe AI Clinical Trial Design Software Sales Value by Country (%), 2025 vs 2032

5.4 Asia Pacific

5.4.1 Asia Pacific AI Clinical Trial Design Software Sales Value, 2021–2032

5.4.2 Asia Pacific AI Clinical Trial Design Software Sales Value by Subregion (%), 2025 vs 2032

5.5 South America

5.5.1 South America AI Clinical Trial Design Software Sales Value, 2021–2032

5.5.2 South America AI Clinical Trial Design Software Sales Value by Country (%), 2025 vs 2032

5.6 Middle East & Africa

5.6.1 Middle East & Africa AI Clinical Trial Design Software Sales Value, 2021–2032

5.6.2 Middle East & Africa AI Clinical Trial Design Software Sales Value by Country (%), 2025 vs 2032

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions AI Clinical Trial Design Software Sales Value Growth Trends, 2021 vs 2025 vs 2032

6.2 Key Countries/Regions AI Clinical Trial Design Software Sales Value, 2021–2032

6.3 United States

6.3.1 United States AI Clinical Trial Design Software Sales Value, 2021–2032

6.3.2 United States AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

6.3.3 United States AI Clinical Trial Design Software Sales Value by Application, 2025 vs 2032

6.4 Europe

6.4.1 Europe AI Clinical Trial Design Software Sales Value, 2021–2032

6.4.2 Europe AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

6.4.3 Europe AI Clinical Trial Design Software Sales Value by Application, 2025 vs 2032

6.5 China

6.5.1 China AI Clinical Trial Design Software Sales Value, 2021–2032

6.5.2 China AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

6.5.3 China AI Clinical Trial Design Software Sales Value by Application, 2025 vs 2032

6.6 Japan

6.6.1 Japan AI Clinical Trial Design Software Sales Value, 2021–2032

6.6.2 Japan AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

6.6.3 Japan AI Clinical Trial Design Software Sales Value by Application, 2025 vs 2032

6.7 South Korea

6.7.1 South Korea AI Clinical Trial Design Software Sales Value, 2021–2032

6.7.2 South Korea AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

6.7.3 South Korea AI Clinical Trial Design Software Sales Value by Application, 2025 vs 2032

6.8 Southeast Asia

6.8.1 Southeast Asia AI Clinical Trial Design Software Sales Value, 2021–2032

6.8.2 Southeast Asia AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

6.8.3 Southeast Asia AI Clinical Trial Design Software Sales Value by Application, 2025 vs 2032

6.9 India

6.9.1 India AI Clinical Trial Design Software Sales Value, 2021–2032

6.9.2 India AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

6.9.3 India AI Clinical Trial Design Software Sales Value by Application, 2025 vs 2032

7 Company Profiles

7.1 Medidata

7.1.1 Medidata Profile

7.1.2 Medidata Main Business

7.1.3 Medidata AI Clinical Trial Design Software Products, Services, and Solutions

7.1.4 Medidata AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.1.5 Medidata Recent Developments

7.2 IQVIA

7.2.1 IQVIA Profile

7.2.2 IQVIA Main Business

7.2.3 IQVIA AI Clinical Trial Design Software Products, Services, and Solutions

7.2.4 IQVIA AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.2.5 IQVIA Recent Developments

7.3 Certara

7.3.1 Certara Profile

7.3.2 Certara Main Business

7.3.3 Certara AI Clinical Trial Design Software Products, Services, and Solutions

7.3.4 Certara AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.3.5 Certara Recent Developments

7.4 Cytel

7.4.1 Cytel Profile

7.4.2 Cytel Main Business

7.4.3 Cytel AI Clinical Trial Design Software Products, Services, and Solutions

7.4.4 Cytel AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.4.5 Cytel Recent Developments

7.5 TriNetX

7.5.1 TriNetX Profile

7.5.2 TriNetX Main Business

7.5.3 TriNetX AI Clinical Trial Design Software Products, Services, and Solutions

7.5.4 TriNetX AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.5.5 TriNetX Recent Developments

7.6 Saama

7.6.1 Saama Profile

7.6.2 Saama Main Business

7.6.3 Saama AI Clinical Trial Design Software Products, Services, and Solutions

7.6.4 Saama AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.6.5 Saama Recent Developments

7.7 Simulations Plus

7.7.1 Simulations Plus Profile

7.7.2 Simulations Plus Main Business

7.7.3 Simulations Plus AI Clinical Trial Design Software Products, Services, and Solutions

7.7.4 Simulations Plus AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.7.5 Simulations Plus Recent Developments

7.8 Statsols

7.8.1 Statsols Profile

7.8.2 Statsols Main Business

7.8.3 Statsols AI Clinical Trial Design Software Products, Services, and Solutions

7.8.4 Statsols AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.8.5 Statsols Recent Developments

7.9 ConcertAI

7.9.1 ConcertAI Profile

7.9.2 ConcertAI Main Business

7.9.3 ConcertAI AI Clinical Trial Design Software Products, Services, and Solutions

7.9.4 ConcertAI AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.9.5 ConcertAI Recent Developments

7.10 Phesi

7.10.1 Phesi Profile

7.10.2 Phesi Main Business

7.10.3 Phesi AI Clinical Trial Design Software Products, Services, and Solutions

7.10.4 Phesi AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.10.5 Phesi Recent Developments

7.11 Faro Health

7.11.1 Faro Health Profile

7.11.2 Faro Health Main Business

7.11.3 Faro Health AI Clinical Trial Design Software Products, Services, and Solutions

7.11.4 Faro Health AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.11.5 Faro Health Recent Developments

7.12 QuantHealth

7.12.1 QuantHealth Profile

7.12.2 QuantHealth Main Business

7.12.3 QuantHealth AI Clinical Trial Design Software Products, Services, and Solutions

7.12.4 QuantHealth AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.12.5 QuantHealth Recent Developments

7.13 Unlearn

7.13.1 Unlearn Profile

7.13.2 Unlearn Main Business

7.13.3 Unlearn AI Clinical Trial Design Software Products, Services, and Solutions

7.13.4 Unlearn AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.13.5 Unlearn Recent Developments

7.14 MMS

7.14.1 MMS Profile

7.14.2 MMS Main Business

7.14.3 MMS AI Clinical Trial Design Software Products, Services, and Solutions

7.14.4 MMS AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.14.5 MMS Recent Developments

7.15 Berry Consultants

7.15.1 Berry Consultants Profile

7.15.2 Berry Consultants Main Business

7.15.3 Berry Consultants AI Clinical Trial Design Software Products, Services, and Solutions

7.15.4 Berry Consultants AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.15.5 Berry Consultants Recent Developments

7.16 ZS

7.16.1 ZS Profile

7.16.2 ZS Main Business

7.16.3 ZS AI Clinical Trial Design Software Products, Services, and Solutions

7.16.4 ZS AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.16.5 ZS Recent Developments

7.17 Clinion

7.17.1 Clinion Profile

7.17.2 Clinion Main Business

7.17.3 Clinion AI Clinical Trial Design Software Products, Services, and Solutions

7.17.4 Clinion AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.17.5 Clinion Recent Developments

7.18 Nurocor

7.18.1 Nurocor Profile

7.18.2 Nurocor Main Business

7.18.3 Nurocor AI Clinical Trial Design Software Products, Services, and Solutions

7.18.4 Nurocor AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.18.5 Nurocor Recent Developments

7.19 Lindus Health

7.19.1 Lindus Health Profile

7.19.2 Lindus Health Main Business

7.19.3 Lindus Health AI Clinical Trial Design Software Products, Services, and Solutions

7.19.4 Lindus Health AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.19.5 Lindus Health Recent Developments

7.20 TrialKey

7.20.1 TrialKey Profile

7.20.2 TrialKey Main Business

7.20.3 TrialKey AI Clinical Trial Design Software Products, Services, and Solutions

7.20.4 TrialKey AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.20.5 TrialKey Recent Developments

7.21 Protocol Builder

7.21.1 Protocol Builder Profile

7.21.2 Protocol Builder Main Business

7.21.3 Protocol Builder AI Clinical Trial Design Software Products, Services, and Solutions

7.21.4 Protocol Builder AI Clinical Trial Design Software Revenue (US$ Million), 2021–2026

7.21.5 Protocol Builder Recent Developments

8 Industry Chain Analysis

8.1 AI Clinical Trial Design Software Value Chain

8.2 AI Clinical Trial Design Software Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Key Suppliers of Raw Materials

8.2.3 Cost Structure

8.3 Midstream Analysis

8.4 Downstream (Customer) Analysis

8.5 Sales Model and Sales Channelss

8.5.1 AI Clinical Trial Design Software Sales Model

8.5.2 Sales Channels

8.5.3 AI Clinical Trial Design Software Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. AI Clinical Trial Design Software Market Trends

Table 2. AI Clinical Trial Design Software Market Drivers & Opportunities

Table 3. AI Clinical Trial Design Software Market Challenges

Table 4. AI Clinical Trial Design Software Market Restraints

Table 5. Global AI Clinical Trial Design Software Revenue by Company (US$ Million), 2021–2026

Table 6. Global AI Clinical Trial Design Software Revenue Market Share by Company (2021–2026)

Table 7. Key Companies’ R&D and Operations Footprint and Headquarters

Table 8. Key Companies AI Clinical Trial Design Software Product Type

Table 9. Key Companies General Availability (GA) Timeline for AI Clinical Trial Design Software

Table 10. Global AI Clinical Trial Design Software Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on AI Clinical Trial Design Software revenue, 2025

Table 12. Mergers & Acquisitions and Expansion Plans

Table 13. Global AI Clinical Trial Design Software Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)

Table 14. Global AI Clinical Trial Design Software Sales Value by Type (US$ Million), 2021–2026

Table 15. Global AI Clinical Trial Design Software Sales Value by Type (US$ Million), 2027–2032

Table 16. Global AI Clinical Trial Design Software Sales Market Share in Value by Type (2021–2026)

Table 17. Global AI Clinical Trial Design Software Sales Market Share in Value by Type (2027–2032)

Table 18. Global AI Clinical Trial Design Software Sales Value by Deployment Model: 2021 vs 2025 vs 2032 (US$ Million)

Table 19. Global AI Clinical Trial Design Software Sales Value by Deployment Model (US$ Million), 2021–2026

Table 20. Global AI Clinical Trial Design Software Sales Value by Deployment Model (US$ Million), 2027–2032

Table 21. Global AI Clinical Trial Design Software Sales Market Share in Value by Deployment Model (2021–2026)

Table 22. Global AI Clinical Trial Design Software Sales Market Share in Value by Deployment Model (2027–2032)

Table 23. Global AI Clinical Trial Design Software Sales Value by Delivery Model: 2021 vs 2025 vs 2032 (US$ Million)

Table 24. Global AI Clinical Trial Design Software Sales Value by Delivery Model (US$ Million), 2021–2026

Table 25. Global AI Clinical Trial Design Software Sales Value by Delivery Model (US$ Million), 2027–2032

Table 26. Global AI Clinical Trial Design Software Sales Market Share in Value by Delivery Model (2021–2026)

Table 27. Global AI Clinical Trial Design Software Sales Market Share in Value by Delivery Model (2027–2032)

Table 28. Global AI Clinical Trial Design Software Sales Value by Trial Stage Coverage: 2021 vs 2025 vs 2032 (US$ Million)

Table 29. Global AI Clinical Trial Design Software Sales Value by Trial Stage Coverage (US$ Million), 2021–2026

Table 30. Global AI Clinical Trial Design Software Sales Value by Trial Stage Coverage (US$ Million), 2027–2032

Table 31. Global AI Clinical Trial Design Software Sales Market Share in Value by Trial Stage Coverage (2021–2026)

Table 32. Global AI Clinical Trial Design Software Sales Market Share in Value by Trial Stage Coverage (2027–2032)

Table 33. Global AI Clinical Trial Design Software Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)

Table 34. Global AI Clinical Trial Design Software Sales Value by Application (US$ Million), 2021–2026

Table 35. Global AI Clinical Trial Design Software Sales Value by Application (US$ Million), 2027–2032

Table 36. Global AI Clinical Trial Design Software Sales Market Share in Value by Application (2021–2026)

Table 37. Global AI Clinical Trial Design Software Sales Market Share in Value by Application (2027–2032)

Table 38. Global AI Clinical Trial Design Software Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032

Table 39. Global AI Clinical Trial Design Software Sales Value by Region (US$ Million), 2021–2026

Table 40. Global AI Clinical Trial Design Software Sales Value by Region (US$ Million), 2027–2032

Table 41. Global AI Clinical Trial Design Software Sales Value by Region (%), 2021–2026

Table 42. Global AI Clinical Trial Design Software Sales Value by Region (%), 2027–2032

Table 43. Key Countries/Regions AI Clinical Trial Design Software Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032

Table 44. Key Countries/Regions AI Clinical Trial Design Software Sales Value, (US$ Million), 2021–2026

Table 45. Key Countries/Regions AI Clinical Trial Design Software Sales Value, (US$ Million), 2027–2032

Table 46. Medidata Basic Information List

Table 47. Medidata Description and Business Overview

Table 48. Medidata AI Clinical Trial Design Software Products, Services, and Solutions

Table 49. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Medidata (2021–2026)

Table 50. Medidata Recent Developments

Table 51. IQVIA Basic Information List

Table 52. IQVIA Description and Business Overview

Table 53. IQVIA AI Clinical Trial Design Software Products, Services, and Solutions

Table 54. Revenue (US$ Million) in AI Clinical Trial Design Software Business of IQVIA (2021–2026)

Table 55. IQVIA Recent Developments

Table 56. Certara Basic Information List

Table 57. Certara Description and Business Overview

Table 58. Certara AI Clinical Trial Design Software Products, Services, and Solutions

Table 59. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Certara (2021–2026)

Table 60. Certara Recent Developments

Table 61. Cytel Basic Information List

Table 62. Cytel Description and Business Overview

Table 63. Cytel AI Clinical Trial Design Software Products, Services, and Solutions

Table 64. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Cytel (2021–2026)

Table 65. Cytel Recent Developments

Table 66. TriNetX Basic Information List

Table 67. TriNetX Description and Business Overview

Table 68. TriNetX AI Clinical Trial Design Software Products, Services, and Solutions

Table 69. Revenue (US$ Million) in AI Clinical Trial Design Software Business of TriNetX (2021–2026)

Table 70. TriNetX Recent Developments

Table 71. Saama Basic Information List

Table 72. Saama Description and Business Overview

Table 73. Saama AI Clinical Trial Design Software Products, Services, and Solutions

Table 74. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Saama (2021–2026)

Table 75. Saama Recent Developments

Table 76. Simulations Plus Basic Information List

Table 77. Simulations Plus Description and Business Overview

Table 78. Simulations Plus AI Clinical Trial Design Software Products, Services, and Solutions

Table 79. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Simulations Plus (2021–2026)

Table 80. Simulations Plus Recent Developments

Table 81. Statsols Basic Information List

Table 82. Statsols Description and Business Overview

Table 83. Statsols AI Clinical Trial Design Software Products, Services, and Solutions

Table 84. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Statsols (2021–2026)

Table 85. Statsols Recent Developments

Table 86. ConcertAI Basic Information List

Table 87. ConcertAI Description and Business Overview

Table 88. ConcertAI AI Clinical Trial Design Software Products, Services, and Solutions

Table 89. Revenue (US$ Million) in AI Clinical Trial Design Software Business of ConcertAI (2021–2026)

Table 90. ConcertAI Recent Developments

Table 91. Phesi Basic Information List

Table 92. Phesi Description and Business Overview

Table 93. Phesi AI Clinical Trial Design Software Products, Services, and Solutions

Table 94. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Phesi (2021–2026)

Table 95. Phesi Recent Developments

Table 96. Faro Health Basic Information List

Table 97. Faro Health Description and Business Overview

Table 98. Faro Health AI Clinical Trial Design Software Products, Services, and Solutions

Table 99. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Faro Health (2021–2026)

Table 100. Faro Health Recent Developments

Table 101. QuantHealth Basic Information List

Table 102. QuantHealth Description and Business Overview

Table 103. QuantHealth AI Clinical Trial Design Software Products, Services, and Solutions

Table 104. Revenue (US$ Million) in AI Clinical Trial Design Software Business of QuantHealth (2021–2026)

Table 105. QuantHealth Recent Developments

Table 106. Unlearn Basic Information List

Table 107. Unlearn Description and Business Overview

Table 108. Unlearn AI Clinical Trial Design Software Products, Services, and Solutions

Table 109. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Unlearn (2021–2026)

Table 110. Unlearn Recent Developments

Table 111. MMS Basic Information List

Table 112. MMS Description and Business Overview

Table 113. MMS AI Clinical Trial Design Software Products, Services, and Solutions

Table 114. Revenue (US$ Million) in AI Clinical Trial Design Software Business of MMS (2021–2026)

Table 115. MMS Recent Developments

Table 116. Berry Consultants Basic Information List

Table 117. Berry Consultants Description and Business Overview

Table 118. Berry Consultants AI Clinical Trial Design Software Products, Services, and Solutions

Table 119. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Berry Consultants (2021–2026)

Table 120. Berry Consultants Recent Developments

Table 121. ZS Basic Information List

Table 122. ZS Description and Business Overview

Table 123. ZS AI Clinical Trial Design Software Products, Services, and Solutions

Table 124. Revenue (US$ Million) in AI Clinical Trial Design Software Business of ZS (2021–2026)

Table 125. ZS Recent Developments

Table 126. Clinion Basic Information List

Table 127. Clinion Description and Business Overview

Table 128. Clinion AI Clinical Trial Design Software Products, Services, and Solutions

Table 129. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Clinion (2021–2026)

Table 130. Clinion Recent Developments

Table 131. Nurocor Basic Information List

Table 132. Nurocor Description and Business Overview

Table 133. Nurocor AI Clinical Trial Design Software Products, Services, and Solutions

Table 134. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Nurocor (2021–2026)

Table 135. Nurocor Recent Developments

Table 136. Lindus Health Basic Information List

Table 137. Lindus Health Description and Business Overview

Table 138. Lindus Health AI Clinical Trial Design Software Products, Services, and Solutions

Table 139. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Lindus Health (2021–2026)

Table 140. Lindus Health Recent Developments

Table 141. TrialKey Basic Information List

Table 142. TrialKey Description and Business Overview

Table 143. TrialKey AI Clinical Trial Design Software Products, Services, and Solutions

Table 144. Revenue (US$ Million) in AI Clinical Trial Design Software Business of TrialKey (2021–2026)

Table 145. TrialKey Recent Developments

Table 146. Protocol Builder Basic Information List

Table 147. Protocol Builder Description and Business Overview

Table 148. Protocol Builder AI Clinical Trial Design Software Products, Services, and Solutions

Table 149. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Protocol Builder (2021–2026)

Table 150. Protocol Builder Recent Developments

Table 151. Revenue (US$ Million) in AI Clinical Trial Design Software Business of Company 40 (2021–2026)

Table 152. Company 40 Recent Developments

Table 153. Key Raw Materials Lists

Table 154. Key Suppliers of Raw Materials Lists

Table 155. AI Clinical Trial Design Software Downstream Customers

Table 156. AI Clinical Trial Design Software Distributors List

Table 157. Research Programs/Design for This Report

Table 158. Key Data Information from Secondary Sources

Table 159. Key Data Information from Primary Sources

List of Figures

Figure 1. AI Clinical Trial Design Software Product Picture

Figure 2. Global AI Clinical Trial Design Software Sales Value, 2021 vs 2025 vs 2032 (US$ Million)

Figure 3. Global AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 4. AI Clinical Trial Design Software Report Years Considered

Figure 5. Global AI Clinical Trial Design Software Players Revenue Ranking (US$ Million), 2025

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by AI Clinical Trial Design Software Revenue in 2025

Figure 7. AI Clinical Trial Design Software Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 8. End-to-End Trial Design Platforms Picture

Figure 9. Protocol Authoring and Optimization Software Picture

Figure 10. Trial Simulation and Outcome Prediction Software Picture

Figure 11. Adaptive and Bayesian Design Software Picture

Figure 12. Feasibility and Enrollment Design Software Picture

Figure 13. Synthetic Control and Digital Twin Software Picture

Figure 14. Global AI Clinical Trial Design Software Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032

Figure 15. Global AI Clinical Trial Design Software Sales Value Market Share by Type, 2025 & 2032

Figure 16. Cloud-Based Software Picture

Figure 17. On-Premises Software Picture

Figure 18. Hybrid Deployment Software Picture

Figure 19. Global AI Clinical Trial Design Software Sales Value by Deployment Model (US$ Million), 2021 vs 2025 vs 2032

Figure 20. Global AI Clinical Trial Design Software Sales Value Market Share by Deployment Model, 2025 & 2032

Figure 21. Standalone Software Picture

Figure 22. Enterprise Platform Suite Picture

Figure 23. Software with Expert Services Picture

Figure 24. Global AI Clinical Trial Design Software Sales Value by Delivery Model (US$ Million), 2021 vs 2025 vs 2032

Figure 25. Global AI Clinical Trial Design Software Sales Value Market Share by Delivery Model, 2025 & 2032

Figure 26. Early-Phase Trial Software Picture

Figure 27. Late-Phase Trial Software Picture

Figure 28. Post-Market Study Software Picture

Figure 29. Multi-Phase Trial Software Picture

Figure 30. Global AI Clinical Trial Design Software Sales Value by Trial Stage Coverage (US$ Million), 2021 vs 2025 vs 2032

Figure 31. Global AI Clinical Trial Design Software Sales Value Market Share by Trial Stage Coverage, 2025 & 2032

Figure 32. Product Picture of Pharmaceutical and Biotechnology Companies

Figure 33. Product Picture of Contract Research Organizations

Figure 34. Product Picture of Medical Device and Diagnostics Companies

Figure 35. Product Picture of Academic and Medical Research Institutions

Figure 36. Product Picture of Government and Nonprofit Research Organizations

Figure 37. Product Picture of Other Clinical Research Organizations

Figure 38. Global AI Clinical Trial Design Software Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032

Figure 39. Global AI Clinical Trial Design Software Sales Value Market Share by Application, 2025 & 2032

Figure 40. North America AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 41. North America AI Clinical Trial Design Software Sales Value by Country (%), 2025 vs 2032

Figure 42. Europe AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 43. Europe AI Clinical Trial Design Software Sales Value by Country (%), 2025 vs 2032

Figure 44. Asia Pacific AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 45. Asia Pacific AI Clinical Trial Design Software Sales Value by Subregion (%), 2025 vs 2032

Figure 46. South America AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 47. South America AI Clinical Trial Design Software Sales Value by Country (%), 2025 vs 2032

Figure 48. Middle East & Africa AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 49. Middle East & Africa AI Clinical Trial Design Software Sales Value by Country (%), 2025 vs 2032

Figure 50. Key Countries/Regions AI Clinical Trial Design Software Sales Value (%), 2021–2032

Figure 51. United States AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 52. United States AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

Figure 53. United States AI Clinical Trial Design Software Sales Value by Application (%), 2025 vs 2032

Figure 54. Europe AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 55. Europe AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

Figure 56. Europe AI Clinical Trial Design Software Sales Value by Application (%), 2025 vs 2032

Figure 57. China AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 58. China AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

Figure 59. China AI Clinical Trial Design Software Sales Value by Application (%), 2025 vs 2032

Figure 60. Japan AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 61. Japan AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

Figure 62. Japan AI Clinical Trial Design Software Sales Value by Application (%), 2025 vs 2032

Figure 63. South Korea AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 64. South Korea AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

Figure 65. South Korea AI Clinical Trial Design Software Sales Value by Application (%), 2025 vs 2032

Figure 66. Southeast Asia AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 67. Southeast Asia AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

Figure 68. Southeast Asia AI Clinical Trial Design Software Sales Value by Application (%), 2025 vs 2032

Figure 69. India AI Clinical Trial Design Software Sales Value (US$ Million), 2021–2032

Figure 70. India AI Clinical Trial Design Software Sales Value by Type (%), 2025 vs 2032

Figure 71. India AI Clinical Trial Design Software Sales Value by Application (%), 2025 vs 2032

Figure 72. AI Clinical Trial Design Software Value Chain

Figure 73. AI Clinical Trial Design Software Cost Structure

Figure 74. Channels of Distribution (Direct Sales, and Distribution)

Figure 75. Bottom-up and Top-down Approaches for This Report

Figure 76. Data Triangulation

Figure 77. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What is the annual compound growth rate of the global AI Clinical Trial Design Software market size from 2026 to 2032? zhanKai

The annual compound growth rate of the global AI Clinical Trial Design Software market is 18.8% 2026 to 2032.

What was the global market size of AI Clinical Trial Design Software in 2032? shouQi

Which region is expected to have the highest market share? shouQi

Which companies rank high in the global AI Clinical Trial Design Software market? shouQi

What was the global market size of AI Clinical Trial Design Software in 2026? shouQi

Related Reports

Global AI Clinical Trial Design Software Market Research Report 2026
The global AI Clinical Trial Design Software market was valued at US$ 486 million in 2025 and is anticipated to reach US$ 1628 million by 2032, at a CAGR of 18.8% from 2026 to 2032.
Published Date: 2026-07-16
Pages: 143
USD 2900.00
(Single User License)
Global AI Clinical Trial Design Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global AI Clinical Trial Design Software market size was US$ 486 million in 2025 and is forecast to reach a readjusted size of US$ 1628 million by 2032 with a CAGR of 18.8% during the forecast period 2026-2032.
Published Date: 2026-07-16
Pages: 156
USD 4250.00
(Single User License)
Global AI Clinical Trial Design Software Market Outlook, In‑Depth Analysis & Forecast to 2032
The global AI Clinical Trial Design Software market is projected to grow from US$ 486 million in 2025 to US$ 1628 million by 2032, at a CAGR of 18.8% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-07-16
Pages: 163
USD 4900.00
(Single User License)

Global AI Clinical Trial Design Software Market Research Report 2026
The global AI Clinical Trial Design Software market was valued at US$ 486 million in 2025 and is anticipated to reach US$ 1628 million by 2032, at a CAGR of 18.8% from 2026 to 2032.
Published: 2026-07-16
Pages: 143
USD 2900.00 (Single User License)
Global AI Clinical Trial Design Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global AI Clinical Trial Design Software market size was US$ 486 million in 2025 and is forecast to reach a readjusted size of US$ 1628 million by 2032 with a CAGR of 18.8% during the forecast period 2026-2032.
Published: 2026-07-16
Pages: 156
USD 4250.00 (Single User License)
Global AI Clinical Trial Design Software Market Outlook, In‑Depth Analysis & Forecast to 2032
The global AI Clinical Trial Design Software market is projected to grow from US$ 486 million in 2025 to US$ 1628 million by 2032, at a CAGR of 18.8% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-07-16
Pages: 163
USD 4900.00 (Single User License)